Gefitinib - Indications, Dosage, Side Effects and Precautions

USDailyMed:Gefitinib AU:C L01EB01(WHO) AU:S4(Prescription only)CA:℞-onlyUK:POM(Prescription only)US:℞-onlyEU:Rx-only N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine 184475-35-2Y 123631 4941 DB00317Y 110217Y S65743JHBS D01977Y CHEBI:49668Y ChEMBL939Y DTXSID8041034 Interactive image C1COCCN1CCCOc2c(OC)cc3ncnc(c3c2)Nc4cc(Cl)c(F)cc4 InChI=‍‍‍‍‍‍​​​‍​​​​​​1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)YKey:XGALLCVXEZPNRQ-UHFFFAOYSA-NY Gefitinib, sold under the brand nameIressa, is amedicationused for certain breast, lung and othercancers. Gefitinib is anEGFR inhibitor, likeerlotinib, which interrupts signaling through theepidermal growth factor receptor(EGFR) in target cells. Therefore, it is only effective in cancers with mutated and overactive EGFR, but resistances to gefitinib can arise through other mutations. It is marketed byAstraZenecaandTeva. Gefitinib is a therapeutic alternative on theWorld Health Organization's List of Essential Medicines.It is available as ageneric medication.